Form 4: Orchestra BioMed CFO Executes Tax-Related Share Withholding

CFO Andrew Taylor reported the withholding of 3,076 shares of Orchestra BioMed common stock to satisfy tax obligations related to RSU vesting.

Summary

• Andrew Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc., reported a transaction involving the withholding of 3,076 shares of common stock.
• The transaction occurred on May 28, 2026, at a price of $3.98 per share.
• The withholding was executed to satisfy tax obligations associated with the vesting of restricted stock units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 629,417 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax transaction rather than a strategic or market-driven move.

Positives

• The transaction was a mandatory tax withholding event rather than a discretionary open-market sale, indicating no change in the executive's long-term confidence in the company.

Negatives

• The transaction resulted in a minor reduction in the executive's direct share ownership.

Risks

• None identified; this is a routine administrative transaction related to equity compensation.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Management Comments

• The filing notes that no shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.

Industry Context

StockSavvy.ai notes that routine tax-related share withholdings are standard practice for executives in the biotechnology sector and do not typically signal shifts in corporate strategy or insider sentiment.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for equity-based compensation in the U.S. biotech industry.
• The use of 'sell-to-cover' or withholding mechanisms is a common, non-discretionary method for managing tax liabilities upon RSU vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was non-discretionary and did not involve open-market selling.

Next Steps

• None mentioned.

Key Dates

Keywords

Orchestra BioMed, OBIO, Form 4, Insider Trading, Tax Withholding, Equity Compensation